Citius Oncology, Inc.
CTOR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851484
No open-market purchases or sales by Citius Oncology, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $9.20M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Citius Oncology, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +2 vs. Q3 2025
- Shares held
- 6.86M
- −1.50M (−17.9%) vs. Q3 2025
- Total value
- $6.86M
- −$10.1M (−59.6%) vs. Q3 2025
- New holders
- 6
- 5 more added
- Sold out
- 4
- 4 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CTOR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $9.20M |
| Q1 2026 | 14 | $8.83M |
| Q4 2025 | 18 | $6.86M |
| Q3 2025 | 16 | $17.0M |
| Q2 2025 | 7 | $989.6K |
| Q1 2025 | 6 | $97.7K |
| Q4 2024 | 11 | $230.2K |
| Q3 2024 | 7 | $57.0K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Citius Oncology, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 23 | $0 | 0.00% | +23 | New |
| Farther Finance Advisors, LLC | 3 | $3 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 214 | $214 | 0.00% | −50−18.9% | Reduced |
| Versant Capital Management, Inc | 1,500 | $1.50K | 0.00% | +1,500 | New |
| Advisor Group Holdings, Inc. | 11,425 | $11.4K | 0.00% | −320−2.7% | Reduced |
| Arkadios Wealth Advisors | 11,666 | $11.7K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 13,360 | $13.4K | 0.00% | +13,360 | New |
| UBS Group AG | 21,464 | $21.5K | 0.00% | +21,409+38,925.5% | Added |
| BlackRock, Inc. | 22,344 | $22.3K | 0.00% | +22,344 | New |
| Two Sigma Investments, LP | 23,515 | $23.5K | 0.00% | +23,515 | New |
| State Street Corp | 42,900 | $42.9K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 45,746 | $45.7K | 0.00% | +23,982+110.2% | Added |
| XTX Topco Ltd | 73,992 | $74.0K | 0.00% | −52,892−41.7% | Reduced |
| IFP Advisors, Inc | 87,424 | $87.4K | 0.00% | +54,209+163.2% | Added |
| Omers Administration Corp | 104,500 | $104.5K | 0.00% | +104,500 | New |
| Geode Capital Management, LLC | 220,047 | $220.0K | 0.00% | +52,875+31.6% | Added |
| Vanguard Group Inc | 596,997 | $597.0K | 0.00% | +416,829+231.4% | Added |
| Armistice Capital, LLC | 5,584,080 | $5.58M | 0.14% | −2,091,831−27.3% | Reduced |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −55,900−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −17,661−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −11,846−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −5−100.0% | Sold out |